Cancer Family
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
CI-CAN-00000039Explore in graph →
Non-malignant864 active trials6 approved drugs159 evidence items
- NCIt
- C35562
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000039Explore in graph →
Clinical trials
3,131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01418001 | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) | terminated | Phase 1 / Phase 2 | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT03393689 | RGD PET/MRI in Sporadic Vestibular Schwannoma | unknown | Phase 2 | 40 | Rigshospitalet, DenmarkOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT02348255 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00387790 | Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jan 4, 2018 | clinicaltrials |
| NCT03390062 | A Study of Apatinib in Recurrent or Recurrent High-grade Glioma | unknown | Phase 2 | 30 | West China HospitalOTHER | 0 | Jan 4, 2018 | clinicaltrials |
| NCT03388372 | Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma | completed | Phase 2 | 39 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT00895180 | Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 80 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 27, 2017 | clinicaltrials |
| NCT02977689 | Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 1 | Dec 20, 2017 | clinicaltrials |
| NCT01753713 | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 33 | Manmeet Ahluwalia, MDOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00362570 | Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | completed | Phase 2 | 1 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 30, 2017 | clinicaltrials |
| NCT01653028 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Nov 30, 2017 | clinicaltrials |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00396019 | Study of PEG-Intron for Plexiform Neurofibromas | completed | Phase 2 | 86 | University of PittsburghOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT03294486 | Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients(ONCOVIRAC) | unknown | Phase 1 / Phase 2 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT01666600 | NOA-12: BIBF1120 and R-RT in Glioblastoma | terminated | Phase 1 / Phase 2 | 63 | Prof. Dr. Wolfgang WickOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT01866449 | Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme | completed | Phase 2 | 24 | University of UlmOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT03090971 | Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 | completed | Phase 2 | 7 | Fundação Educacional Serra dos ÓrgãosOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT00045708 | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2017 | clinicaltrials |
| NCT03310372 | Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme(TEMOFRAC) | completed | Phase 2 | 46 | Central Hospital, Nancy, FranceOTHER | 0 | Oct 17, 2017 | clinicaltrials |
| NCT01759810 | Proteome-based Personalized Immunotherapy of Glioblastoma | unknown | Phase 2 / Phase 3 | 60 | NeuroVita ClinicOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02987010 | Phase 2 Study of IDH305 in Low Grade Gliomas | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | Oct 11, 2017 | clinicaltrials |
| NCT01310868 | Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma | completed | Phase 2 | 59 | University College, LondonOTHER | 1 | Oct 5, 2017 | clinicaltrials |
| NCT00575796 | Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs) | unknown | Phase 2 | 50 | The Hospital for Sick ChildrenOTHER | 1 | Sep 20, 2017 | clinicaltrials |
| NCT01508117 | Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients | terminated | Phase 2 | 1 | University of CincinnatiOTHER | 1 | Sep 19, 2017 | clinicaltrials |
| NCT00187486 | Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors | completed | Phase 2 | 66 | University of California, San FranciscoOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT00003470 | Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma(AA) | completed | Phase 2 | 27 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00003477 | Antineoplaston Therapy in Treating Children With Visual Pathway Glioma(VPG) | completed | Phase 2 | 12 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00326872 | AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine | terminated | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2017 | clinicaltrials |
| NCT02029573 | Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma(ART) | completed | Phase 2 | 36 | King Fahad Medical CityOTHER_GOV | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00980343 | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00727506 | BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma | completed | Phase 2 | 151 | Boehringer IngelheimINDUSTRY | 2 | Aug 15, 2017 | clinicaltrials |
| NCT00540722 | Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2017 | clinicaltrials |
| NCT01465347 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 59 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Jul 14, 2017 | clinicaltrials |
| NCT03212235 | Hypofractionated Radiation Therapy for Glioblastoma | unknown | Phase 2 | 58 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00823797 | Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma | completed | Phase 2 | 45 | University of WashingtonOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT01140360 | Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas(0908-09) | completed | Phase 1 / Phase 2 | 21 | Kent RobertsonOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01290263 | Amgen 386 for Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01413438 | Bevacizumab With or Without Surgery for Adult Glioblastomas | withdrawn | Phase 2 | 0 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT02848794 | Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma | unknown | Phase 1 / Phase 2 | 40 | The First People's Hospital of LianyungangOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT00112866 | Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme | terminated | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00392171 | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | completed | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00424554 | Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) | completed | Phase 2 | 40 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00684567 | Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED) | completed | Phase 2 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT01310855 | Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 38 | University College, LondonOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00345163 | A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)(BRAIN) | completed | Phase 2 | 167 | Genentech, Inc.INDUSTRY | 0 | May 16, 2017 | clinicaltrials |
| NCT00783393 | SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) | completed | Phase 2 | 32 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT00589706 | A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas | completed | Phase 2 | 11 | Drexel University College of MedicineOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01122901 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | May 3, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Jan 11, 2018source: clinicaltrials